Apogee Therapeutics is committed to maintaining your privacy and recognizes the importance of providing protection for any personal data that you choose to share with us or that we maintain about you.

Apogee Therapeutics, Inc.

Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological and inflammatory disorders. 

Venrock Healthcare Capital Partners

Wellington Management

OrbiMed

Perceptive Advisors

RA Capital Management

RTW Investments

Deep Track Capital

Fairmount Funds Management

Fidelity

Fidelity Management and Research Company

Apogee Therapeutics

We are excited to share that Apogee CMO Carl Dambkowski has been named to this year's In Vivo Rising Leaders list, honoring entrepreneurs and innovators who represent the next wave of creativity in #healthcare. We are grateful to have leaders like Carl paving the way for our innovations in I&I therapies to make an impact and never stopping at “good enough.” Congratulations, Carl!

We are thrilled to announce the first healthy volunteer participants have been dosed in the Phase 1 clinical trial of APG808, our novel half-life extended IL-4Rα antibody for the treatment of #COPD and other inflammatory diseases. We expect to report interim subcutaneous safety and pharmacokinetic data in the second half of this year. CEO Michael Henderson shares more below. https://lnkd.in/e3tQyXmD

A big thank you to Nasdaq for joining us to celebrate the closing of our upsized $483M follow-on financing, extending our cash runway into Q1 2028. At Apogee, we are dedicated to advancing our programs to transform the I&I space for patients with high unmet needs and refuse to stop at “good enough.”

We are pleased to announce the closing of our upsized $483M public offering, extending our cash runway into Q1 2028. Full details below. https://lnkd.in/eAF-FTmj

We recently reported pipeline progress and fourth quarter and full year 2023 financial results. This includes the positive interim results from our APG777 Phase 1 study as well as an update on the Phase 1 clinical study of APG808, a potentially best-in-class antibody for chronic obstructive pulmonary disease (#COPD) and asthma, which is set to start ahead of schedule in the first half of this year. Read more below. https://lnkd.in/eNKSCK8m

Today we announced positive Phase 1 interim data from the first-in-human study of our lead program, APG777. Initial data show APG777 was well tolerated in healthy volunteers and initial PK data support potential best-in-class dosing of every 3 or 6 months. Based on these findings, we plan to accelerate our timelines again and initiate a Phase 2 clinical trial of APG777 in moderate-to-severe #atopicdermatitis in the first half of this year. Read more below. https://lnkd.in/eZrX_Uzh

COM:APOGEETHERAPEUTICS

Apogee Therapeutics, Inc.